Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Disease mechanisms

Topic: Brain proteins, microglia and lab models

Aggregation of microtubule-associated tau protein is a distinct hallmark of several neurodegenerative disorders such as Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), and progressive supranuclear palsy (PSP). Tau oligomers are suggested to be the primary neurotoxic species that initiate aggregation and propagate prion-like structures. Furthermore, different diseases are shown to have distinct structural characteristics of aggregated tau, denoted as polymorphs. Here, we investigate the structural and functional differences of amplified brain-derived tau oligomers (aBDTOs) from AD, DLB, and PSP. Our results indicate that the aBDTOs possess different structural and morphological features that impact neuronal function, gene regulation, and ultimately disease progression. The distinct tau oligomeric polymorphs may thus contribute to the development of clinical phenotypes and shape the progression of diseases. Our results can provide insight into developing personalized therapy to target a specific neurotoxic tau polymorph. Different aggregation characteristics and stability profiles of tau oligomeric polymorphs highlight the importance of studying the tau polymorphs to shed light on the functional differences and neuropathological heterogeneity in tauopathies.

Key findings

Why it matters

Tau oligomers amplified from the brains of people with Alzheimer's disease, dementia with Lewy bodies, and progressive supranuclear palsy differed in structure and stability and affected neuronal function differently. This suggests that therapies might one day be tailored to specific tau forms, but the work is laboratory-based and no treatment is established.

Study details

How this study scored 45/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 3 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multi-centre collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 45 of 100.45 of 100 points earned55 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Communications Biology)
Journal's citation record 1 / 4 Communications Biology: journal h-index 142 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 35 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 11.7 citations a year over 3 year(s) since 2025
Impact for its field and year 4 / 6 Cited 19.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 2 / 4 Cited 35 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Rakez Kayed: h-index 76 (OpenAlex, whole career)
Institution's track record 1 / 3 The Ohio State University: institution h-index 1,378 (OpenAlex)
Multi-centre collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39809992)
Free to read 2 / 2 Free to read
Total 45 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Cascio, F. L., Park, S., Sengupta, U., Puangmalai, N., Bhatt, N. N., Shchankin, N., et al. (2025). Brain-derived tau oligomer polymorphs: distinct aggregations, stability profiles, and biological activities. Communications Biology. https://doi.org/10.1038/s42003-025-07499-w

Vancouver

Cascio FL, Park S, Sengupta U, Puangmalai N, Bhatt NN, Shchankin N, et al. Brain-derived tau oligomer polymorphs: distinct aggregations, stability profiles, and biological activities. Communications Biology. 2025. doi:10.1038/s42003-025-07499-w. PMID: 39809992.

BibTeX

@article{cascio2025-39809992,
  author  = {Cascio, Filippa Lo and Park, S.J. and Sengupta, Urmi and Puangmalai, Nicha and Bhatt, Nemil N. and Shchankin, Nikita and Jerez, Cynthia and Moreno, Naomi and others},
  title   = {{Brain-derived tau oligomer polymorphs: distinct aggregations, stability profiles, and biological activities}},
  journal = {Communications Biology},
  year    = {2025},
  doi     = {10.1038/s42003-025-07499-w},
  pmid    = {39809992},
  url     = {https://doi.org/10.1038/s42003-025-07499-w}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Disease mechanisms

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Similar studies

More on Disease mechanisms

See all studies in Disease mechanisms →